Table 2.
Short term (24-week) regimen durability and virologic failure among 11,338 antiretroviral naïve HIV-infected patients in the Antiretroviral Therapy Cohort Collaboration (ART-CC, plasma HIV RNA >500 copies/mL) initiating ART with zidovudine and lamivudine stratified by 3rd drug, 2000 – 2005.
| Odds ratio (95%CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 3rd Drug | Obs. | No longer on initial regimen at 24 weeks | Obs. | 24 week virologic failure ART-CC (plasma HIV RNA >500 c/mL) | |||||
| N (%) | Crude | Adjusteda | N (%) | Crude | Adjusteda | ||||
| EFV | 3,258 | 679 (21) | 1 | 1 | 3,087 | 383 (12) | 1 | 1 | |
| NVP | 1,759 | 448 (25) | 1.30 (1.13, 1.49) | 1.30 (1.13, 1.51) | 1,776 | 348 (20) | 1.72 (1.47, 2.02) | 1.87 (1.58, 2.22) | |
| LPV/r | 2,518 | 622 (25) | 1.25 (1.10, 1.41) | 1.04 (0.91, 1.19) | 2,457 | 365 (15) | 1.23 (1.06, 1.44) | 1.32 (1.12, 1.57) | |
| NFV | 1,715 | 490 (29) | 1.52 (1.33, 1.74) | 1.39 (1.20, 1.60) | 1,829 | 593 (32) | 3.39 (2.93, 3.92) | 3.20 (2.74, 3.74) | |
| ABC | 2,088 | 432 (21) | 0.99 (0.87, 1.13) | 0.94 (0.81, 1.08) | 2,045 | 486 (24) | 2.20 (1.90, 2.55) | 2.13 (1.82, 2.50) | |
| Table 2a. Sensitivity analysis of short-term (24-week) regimen durability and virologic failure among 13,546 antiretroviral naïve HIV-infected patients in the Antiretroviral Therapy Cohort Collaboration (ART-CC, plasma HIV RNA >500 copies/mL) initiating ART with zidovudine and lamivudine stratified by 3rd drug (missing data = failure), 2000 – 2005. | |||||||
|---|---|---|---|---|---|---|---|
| Odds ratio (95%CI) | |||||||
| 3rd Drug | Obs. | No longer on initial regimen at 24 weeks | 24 week virologic failure ART-CC (plasma HIV RNA >500 c/mL) | ||||
| N (%) | Crude | Adjusteda | N (%) | Crude | Adjusteda | ||
| EFV | 3,788 | 1,209 (32) | 1 | 1 | 1,084 (29) | 1 | 1 |
| NVP | 2,151 | 840 (39) | 1.37 (1.22, 1.53) | 1.29 (1.14, 1.45) | 723 (34) | 1.26 (1.13, 1.42) | 1.44 (1.27, 1.63) |
| LPV/r | 2,875 | 979 (34) | 1.10 (0.99, 1.22) | 1.04 (0.92, 1.16) | 783 (27) | 0.93 (0.84, 1.04) | 1.03 (0.91, 1.16) |
| NFV | 2,217 | 992 (45) | 1.73 (1.55, 1.92) | 1.54 (1.37, 1.72) | 981 (44) | 1.98 (1.77, 2.21) | 1.98 (1.76, 2.22) |
| ABC | 2,515 | 859 (34) | 1.11 (0.99, 1.23) | 1.01 (0.90, 1.14) | 956 (38) | 1.53 (1.37, 1.70) | 1.53 (1.36, 1.72) |
EFV, efavirenz; NVP, nevirapine; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; ABC, abacavir
a
Multivariable logistic regression models adjusted for age, sex, IDU, entry CD4, entry HIV RNA, year starting ART, and cohort.